Clinical Practice Guidelines for Posmenopausal, Glucocorticoid-induced and Male Osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd Updated Version 2014)
Overview
Affiliations
These guidelines update issues covered in previous versions and introduce new ones that have arisen in recent years. The former refer mainly to the therapeutic developments that have been made during this time (zoledronate, denosumab, bazedoxifene), which have led to a change in the drug selection algorithm. The latter deal with therapeutic management, the description of new adverse effects (which have led to changes in therapeutic behaviour patterns, as is the case with atypical fracture of the femur), treatment duration (with consideration for the so-called "therapeutic holidays"), the so-called sequential treatment and changes in treatment imposed by certain circumstances. A new algorithm has been introduced for sequential treatment. Attention has also been paid to vertebroplasty and kyphoplasty.
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.
Grygorieva N, Kovalenko V, korzh M, Tronko M, Golovach I, Dedukh N Arch Osteoporos. 2025; 20(1):31.
PMID: 39992470 DOI: 10.1007/s11657-025-01512-9.
Mingot-Castellano M, Canaro Hirnyk M, Sanchez-Gonzalez B, Alvarez-Roman M, Barez-Garcia A, Bernardo-Gutierrez A J Clin Med. 2023; 12(20).
PMID: 37892566 PMC: 10607106. DOI: 10.3390/jcm12206422.
Acquired Haemophilia A: A Review of What We Know.
Mingot-Castellano M, Rodriguez-Martorell F, Nunez-Vazquez R, Marco P J Blood Med. 2022; 13:691-710.
PMID: 36447782 PMC: 9701517. DOI: 10.2147/JBM.S342077.
Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M J Bone Miner Metab. 2021; 39(6):1019-1030.
PMID: 34125296 DOI: 10.1007/s00774-021-01236-z.
Update on Glucocorticoid Induced Osteoporosis.
Cho S, Sung Y Endocrinol Metab (Seoul). 2021; 36(3):536-543.
PMID: 34107602 PMC: 8258322. DOI: 10.3803/EnM.2021.1021.